NO20050146D0 - N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon - Google Patents

N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon

Info

Publication number
NO20050146D0
NO20050146D0 NO20050146A NO20050146A NO20050146D0 NO 20050146 D0 NO20050146 D0 NO 20050146D0 NO 20050146 A NO20050146 A NO 20050146A NO 20050146 A NO20050146 A NO 20050146A NO 20050146 D0 NO20050146 D0 NO 20050146D0
Authority
NO
Norway
Prior art keywords
useful
treatment
cns disorders
disorders due
diazocycloalkanes
Prior art date
Application number
NO20050146A
Other languages
English (en)
Other versions
NO20050146L (no
Inventor
Gianni Motta
Carlo Riva
Rodolfo Testa
Amedeo Leonardi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of NO20050146D0 publication Critical patent/NO20050146D0/no
Publication of NO20050146L publication Critical patent/NO20050146L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20050146A 2002-06-14 2005-01-11 N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon NO20050146L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001328A ITMI20021328A1 (it) 2002-06-14 2002-06-14 Nuove piperazine 1,4 - disostituite
PCT/EP2003/006280 WO2003106444A1 (en) 2002-06-14 2003-06-16 N,n-disubstituted diazocycloalkanes useful for the treatment of cns disorders due to serotonergic dysfunction

Publications (2)

Publication Number Publication Date
NO20050146D0 true NO20050146D0 (no) 2005-01-11
NO20050146L NO20050146L (no) 2005-03-14

Family

ID=29727277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050146A NO20050146L (no) 2002-06-14 2005-01-11 N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon

Country Status (19)

Country Link
US (1) US20060148821A1 (no)
EP (1) EP1515961A1 (no)
JP (1) JP2005538063A (no)
CN (1) CN1662516A (no)
AU (1) AU2003276979A1 (no)
BR (1) BR0311805A (no)
CA (1) CA2489450A1 (no)
EA (1) EA007503B1 (no)
HR (1) HRP20050034A2 (no)
IL (1) IL165568A0 (no)
IT (1) ITMI20021328A1 (no)
MX (1) MXPA04012602A (no)
NO (1) NO20050146L (no)
NZ (1) NZ537469A (no)
PL (1) PL372531A1 (no)
RS (1) RS108904A (no)
TW (1) TW200400947A (no)
WO (1) WO2003106444A1 (no)
ZA (1) ZA200500318B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293804B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Diarilalchilpiperazine attive sulle basse vie urinarie
JP2001512110A (ja) * 1997-08-01 2001-08-21 レコルダチ エッセ．ア．，ケミカル アンド ファーマシューティカル カンパニー １，４−ジ置換ピペラジン
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors

Also Published As

Publication number Publication date
NZ537469A (en) 2006-07-28
BR0311805A (pt) 2005-03-15
WO2003106444A8 (en) 2004-08-12
HRP20050034A2 (en) 2005-08-31
ZA200500318B (en) 2006-07-26
PL372531A1 (en) 2005-07-25
MXPA04012602A (es) 2005-09-30
WO2003106444A1 (en) 2003-12-24
CN1662516A (zh) 2005-08-31
EA200500023A1 (ru) 2005-06-30
EA007503B1 (ru) 2006-10-27
ITMI20021328A1 (it) 2003-12-15
NO20050146L (no) 2005-03-14
RS108904A (en) 2007-02-05
US20060148821A1 (en) 2006-07-06
AU2003276979A1 (en) 2003-12-31
CA2489450A1 (en) 2003-12-24
IL165568A0 (en) 2006-01-15
JP2005538063A (ja) 2005-12-15
EP1515961A1 (en) 2005-03-23
TW200400947A (en) 2004-01-16

Similar Documents

Publication Publication Date Title
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
GB0504828D0 (en) Therapeutic agents
IS8023A (is) Samsett meðferð til að meðhöndla ónæmisbólgusjúkdóma
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
MY142329A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
IS7945A (is) 4,5-díarýlþíasólafleiður sem CB-1 tenglar
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
IS8349A (is) 2,4-pýrimídíndíamín gagnleg í meðhöndlun æxlissjúkdóma, bólgu- og ónæmiskerfissjúkdóma
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
EP1581206A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH 2,3-BENZODIAZEPINES
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
NO20050885D0 (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
NO20050146L (no) N,N-disubstituerte diazocykloalkaner nyttige i behandling av CNS-forstyrrelser grunnet serotonergisk dysfunksjon
DE60331769D1 (de) Sten in der behandlung von u.a. sexueller dysfunktion
DE60111379D1 (de) Indolderivate zum gebrauch in der behandlung von zns-störungen
WO2005018576A3 (en) N-desmethyl-n-substituted-11-deoxyerythromycin compounds
WO2004014847A8 (en) Mcp-1 receptor antagonists and method of use thereof
NO20024331D0 (no) Behandling av lidelser relatert til det serotonerge system

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application